TB-500 and Joint Pain: What Has Been Studied

What the research covers

No study of TB-500 for joint pain, in people or animals, was found. Its key ingredient is a lab-made copy of a short piece of thymosin beta-4, a larger natural protein. The piece is 7 amino acids long.

A PubMed search on 27 September 2026 paired TB-500 with five joint terms, such as arthritis and knee. It found two records, both reviews. It found no trial of the full thymosin beta-4 protein for knee pain or arthritis either.

The closest human report is a knee chart review from one Florida clinic. Four people got knee joint shots of BPC-157 plus thymosin beta-4, and 3 of them improved. The report names thymosin beta-4, not TB-500. Pain was rated by phone, and no specific tools measured function.

The animal and lab data come from the full protein. In a rodent (rat) study, thymosin beta-4 placed in a cut knee ligament improved healing at 4 weeks. The fibres were more even and the tissue was stronger. In a lab study of cartilage cells, the full protein raised output of an enzyme called MMP-9. No study found tested whether TB-500 rebuilds cartilage.

Sources

1. Lee E, Padgett B Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med (2021). PMID 34324435 Human chart review; 4 of 16 people got knee joint injections of BPC-157 plus thymosin beta-4 (TB4); 75% of those 4 improved. TB-500 not named.
2. Xu B, Yang M, Li Z, et al. Thymosin beta4 enhances the healing of medial collateral ligament injury in rat. Regul Pept (2013). PMID 23523891 doi:10.1016/j.regpep.2013.03.026 Rodent (rat), cut knee ligament; 1 microgram of full-length thymosin beta-4 in fibrin sealant; better fibre alignment and strength at 4 weeks.
3. Blain EJ, Mason DJ, Duance VC The effect of thymosin beta4 on articular cartilage chondrocyte matrix metalloproteinase expression. Biochem Soc Trans (2002). PMID 12440937 doi:10.1042/bst0300879 Cells: cartilage chondrocytes treated with thymosin beta-4 for 4 hours raised pro-MMP 9 expression and activation.
4. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta(4), in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A (2012). PMID 23084823 doi:10.1016/j.chroma.2012.09.043 Identifies the key ingredient of TB-500 as acetylated LKKTETQ, the 17-23 segment of thymosin beta-4.
5. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal (2012). PMID 22962027 doi:10.1002/dta.1402 Chemical analysis identifying Ac-LKKTETQ, the acetylated 17-23 fragment of human thymosin beta-4, in TB-500.